Chelation Partners

Chelation Partners is the former name of Fe Pharmaceuticals, a private Canadian/U.S. biotech developing iron-binding polymer therapeutics for diseases driven by dysregulated iron biology. Its lead program, DIBI, is a water-soluble, non-toxic iron-binding copolymer being developed primarily as a broad-spectrum anti-infective for bacterial and fungal infections, including antimicrobial-resistant pathogens, and for sepsis. The company also describes potential applications of the same platform in inflammatory disorders and cancer. Chelation Partners repositioned under the Fe Pharmaceuticals name to reflect a broader focus on iron management in disease, but the legacy Chelation Partners name still appears on older patents, press releases, and company profiles. Overall, it is a preclinical platform biotech centered on iron sequestration as a therapeutic mechanism.